Sapienza University researchers gain access to Elsevier's Reaxys workflow solution for research chemists

NewsGuard 100/100 Score

Elsevier and Sapienza University of Rome today announced a new agreement, providing researchers at the university with access to Reaxys (http://www.info.reaxys.com/), Elsevier's workflow solution for research chemists. Reflecting the way chemists think and work, Reaxys will enable researchers at Sapienza to quickly find the chemistry relevant for their needs and thereby raise their performance and output.

Marina Dalla Torre, Director of the Sapienza Chemistry Library, said of the purchase, "From the first time we interacted with the product, it was clear that it was a completely different one - user friendly and liked by our students. The new access model also made possible to share this resource with the Department of Pharmacology, and we are sure that other departments will be interested as well."

Prof. Aldo Lagana, Sapienza's Head of Chemistry, added, "My role is to support the sharing of chemistry knowledge and to provide researchers with the best way to improve their performances, particularly during this difficult economic period. Many colleagues have expressed their strong interest in Reaxys, and I believe that their work, and the department as a whole, will benefit from using it."

Offering experimentally validated information, Reaxys combines reaction and substance data in organic, organometallic, inorganic and physical chemistry with synthesis planning. Researchers can get the information they need in a single overview, from source publications carefully selected for their importance and relevance to research chemists.

"We have invested considerable time and effort to ensure that Reaxys mirrors a chemist's research workflow" said Mark van Mierle, Managing Director for Elsevier Information Systems. "This, combined with a simple campus-wide access mechanism, will enable researchers to quickly identify the most important and relevant information."

Source:

Elsevier Properties and Elsevier

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Expanding research and clinical options for children with cancer